Cargando…
Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach
PURPOSE: A differential release fixed dose matrix tablet of amlodipine besylate (AML-B) and simvastatin (SIM) was formulated to enhance patient compliance. MATERIAL AND METHOD: In the first phase, release controlling parameters of AML-B and SIM granules were identified and in the second phase a fixe...
Autores principales: | Kanwal, Ummarah, Mukhtar, Shahid, Waheed, Muzzamil, Mehreen, Arifa, Abbas, Nasir, Shamim, Rahat, Hussain, Khalid, Rasool, Fatima, Hussain, Amjad, Bukhari, Nadeem Irfan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164448/ https://www.ncbi.nlm.nih.gov/pubmed/34079222 http://dx.doi.org/10.2147/DDDT.S240506 |
Ejemplares similares
-
QbD Consideration for Developing a Double-Layered Tablet into a Single-Layered Tablet with Telmisartan and Amlodipine
por: Kim, Joo-Eun, et al.
Publicado: (2022) -
Formulation and Evaluation of S-(-)-Amlodipine Besylate and Nebivolol Hydrochloride Tablets
por: Shaikh, S.A, et al.
Publicado: (2010) -
Design and Optimization of Lornoxicam Dispersible Tablets Using Quality by Design (QbD) Approach
por: Almotairi, Nawaf, et al.
Publicado: (2022) -
Kinetic spectrophotometric method for determination of amlodipine besylate in its pharmaceutical tablets
por: Mahmoud, Ashraf M., et al.
Publicado: (2012) -
Industrial application of QbD and NIR chemometric models in quality improvement of immediate release tablets
por: Ramadan, Ahmed, et al.
Publicado: (2021)